Trials / Sponsors / Kyverna Therapeutics
Kyverna Therapeutics
Industry · 7 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome | — | 2025-11-24 |
| Active Not Recruiting | KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Stiff-Person Syndrome, SPS | Phase 2 | 2024-09-25 |
| Active Not Recruiting | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis | Phase 2 | 2024-09-20 |
| Recruiting | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Myasthenia Gravis, Generalized Myasthenia Gravis | Phase 2 / Phase 3 | 2024-08-28 |
| Active Not Recruiting | KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria | Phase 1 / Phase 2 | 2024-08-06 |
| Active Not Recruiting | KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractor Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV | Phase 1 / Phase 2 | 2023-04-28 |
| Active Not Recruiting | KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractor Lupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | Phase 1 / Phase 2 | 2022-12-01 |